(1997; 175 pages)
V. Anticipated Outcomes
1. The project will apply a systematic cross-national method for the assessment of pharmaceutical policy performance, using summative and formative evaluation techniques, through the standardized indicators and the political mapping technique.
2. The assessment of pharmaceutical policy performance will provide the basis for generating hypotheses to explain how different pharmaceutical policies, especially different public/private mixes, can affect the performance of the pharmaceutical sector.
3. The project will assist policy-makers responsible for pharmaceutical policy in identifying and substantiating specific strengths and weaknesses of existing policy, from national and cross-national perspectives, and in formulating strategies to improve the implementation of pharmaceutical policy.
4. The project will provide field testing of the standard indicators and the political mapping technique in a series of countries, and their potential development into a method of policy analysis and rapid assessment of pharmaceutical sector performance.
5. The project will facilitate the collection of data for the WHO's forthcoming World Drug Situation Report.
6. The project will identify specific policy innovations from cross-national learning that could improve the design and implementation of pharmaceutical policy within each country, and will propose ways to improve the political feasibility of implementing those innovations within a specific political context.
7. The project will enhance the capacity of Essential National Health Research within each country, through the development and application of the policy performance assessment methodology and the political mapping methodology, both of which can be applied to other areas of health policy.
8. The project will provide an impetus for international agencies to reconsider their own policies for the pharmaceutical sector, and will assist in strengthening the policy analysis capabilities of international agencies involved in supporting the development of national pharmaceutical policy.